PULSAR and Real-World Retrospective study of PUL in urinary retention patients

What is it about?

This study compares the safety and efficacy of prostatic urethral lift (PUL) in acute urinary retention (AUR) patients within a controlled (PULSAR) and real-world setting (Real-World Retrospective study). 73% of PULSAR subjects were catheter independent and free from surgical reintervention at 12 months post-PUL. Success was associated with higher voiding efficiency during the perioperative period. In the combined PULSAR and RWRr retention groups, logistic regression revealed that procedural age <70 years and higher bladder voiding efficiency (BVE) were associated with success. Lower baseline PSA and PVR, younger age, and shorter pre-procedure catheter durations drove successful outcomes in AUR patients undergoing PUL.

Featured Image

Why is it important?

This research is important because acute urinary retention (AUR) is a significant health issue that can lead to long-term complications and reduced quality of life for patients. Benign prostatic hyperplasia (BPH) is a common cause of AUR, and it is essential to find effective treatments to relieve the obstruction and improve patient outcomes. Prostatic urethral lift (PUL) is a minimally invasive procedure that has shown promise in treating AUR patients, and this research provides valuable insights into the safety and efficacy of the procedure in real-world and controlled settings. Key Takeaways: 1. PUL was successful in treating AUR patients in both controlled (PULSAR) and real-world (RWR) settings. 2. Lower baseline prostate-specific antigen (PSA), prostate volume, and pre-procedural catheter duration were associated with successful outcomes in AUR patients undergoing PUL. 3. Higher voiding efficiency during the perioperative period was also associated with a successful response to treatment. 4. PUL is a cost-effective procedure compared to traditional surgical options like transurethral resection of the prostate (TURP) and holmium laser enucleation of the prostate (HoLEP). 5. The study findings suggest that PUL may be a valuable treatment option for AUR patients, particularly those with lower baseline PSA and shorter pre-procedure catheter durations.